Drugs for enlarged prostate, baldness may boost risk of prostate cancer
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $1.44 a week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $5.77 plus GST every four weeks. After 52 weeks, price increases to the regular rate of $19.95 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 19/03/2012 (5328 days ago), so information in it may no longer be current.
OTTAWA – Health Canada is warning that certain drugs used to treat an enlarged prostate or male-pattern baldness may increase the risk of a serious form of prostate cancer.
The drug finasteride, sold under the brand names Proscar and Propecia and their generic equivalents, is prescribed to treat both enlarged prostate and male-pattern baldness.
Dutasteride, available under the brand names Avodart and Jalyn, is also used to treat an enlarged prostate, a condition also known as benign prostatic hyperplasia.
Health Canada says finasteride and dutasteride may be associated with a higher risk of developing high-grade prostate cancer, an aggressive type of the disease that can grow and spread quickly.
The department says high-grade prostate cancer is rare, and the increased risk seen with finasteride and dutasteride is still considered very small.
The new safety information is based on a Health Canada review of two large international clinical trials that showed that long-term daily use of finasteride and dutasteride in men 50 and older was linked to a small increased risk of high-grade prostate cancer.
In the studies, long-term use was described as four years or more.
The risk was shown in the five milligram dosage of finasteride (sold as Proscar). The one-mg strength of the drug (sold as Propecia) was not included in these trials, but a potential risk has not been ruled out, Health Canada says.
The trials were conducted to see if the two drugs could be used to prevent prostate cancer. Both studies found the possible benefit of preventing low-grade prostate cancer was small compared to the risk of developing the high-grade form of the disease.
Finasteride and dutasteride are not approved for the prevention of prostate cancer in Canada.
Patients should discuss questions or concerns about treatment with finasteride or dutasteride with their doctor, and should not stop taking their medication unless advised to do so.
